Hypermune

Main information

  • Trade name:
  • Hypermune-Re Equine Plasma Immunological Intravenous Infusion Solution
  • Pharmaceutical form:
  • Solution for infusion
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Hypermune-Re Equine Plasma Immunological Intravenous Infusion Solution
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • BEE
  • Therapeutic area:
  • Horses Young

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0298/001
  • Authorization date:
  • 28-05-2008
  • EU code:
  • UK/V/0298/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

RevisedMay2012

AN:01006/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

HYPERMUNE-REEquinePlasma

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

QualitativeCompositionFrozenEquinePlasma

QuantitativeComposition

Activesubstances:

EquineIg G≥24g/l

EquineTotalProtein≥50g/l

AntibodiestoRhodococcusequi≥40%VILstandard

Excipient:

AcidCitrateDextrose-Atoensurecitratecontent10-20mmols/l

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Plasmaforintravenousinfusion,afterthawing.

4. CLINICALPARTICULARS

4.1 Targetspecies

Foalsfrom24hourstosixdaysofage.

4.2 Indicationsforuse,specifyingthetargetspecies

ForfoalswithFailureofPassiveTransfer

ToraisethelevelofcirculatingIgGinneonatalfoalswhichhavebeenshowntohavelow

levels(lessthan4g/l).Theraisedlevelhasbeendemonstratedapproximately24hours

afteradministrationbutthedurationoftheeffectisnotknown.

ForfoalswithNormalpassiveTransfer

ToraisethelevelofRhodococcusequiantibodies.Theraisedlevelhasbeen

demonstratedapproximately24hoursafteradministrationandraisedlevelsthough

declininggenerallylastforupto21days.

4.3 Contraindications

None

RevisedMay2012

AN:01006/2011

Page2of6

4.4 Specialwarnings<foreachtargetspecies>

ItisrecommendedthatappropriateRhodococcuscontrolmeasuresshouldbe

implementedtocontroldisease.Suchmeasuresincludeavoidanceofovercrowding,

controllingpaddockdustlevels,provisionofshadefortheanimals,removaloffaecesfrom

pasturesandclosemonitoringoffoalhealth.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Donotadministermorethan2dosestoananimal.

Ifaseconddoseisrequireddonotadministerthisbefore24hours.

Toreduceriskofadversereactions:

TransfusionReactions.Carefulmonitoring,especiallyatthestartandthroughoutthe

transfusionisessential.Distinctionmustbemadebetweenreactiontorestraintand

catheterisation and signs attributable to transfusion reaction. If tachycardia,

hyperventilatingortremblingoccurs,thetransfusionshouldbesloweddownorstopped

altogether.Ifsignsabatewithinfiveminutes,astheyshould,thenthetransfusionshould

becontinued.Iftheyrecuragain,thetransfusionshouldbestoppedentirely.

Anaphylaxis.Carefulmonitoring,especiallyatthestartandthroughoutthetransfusion,is

essential.Iftachycardia,hyperventilatingortremblingoccurs,thetransfusionshouldbe

sloweddownorstoppedaltogether.Ifsignsabatewithinfiveminutes,astheyshould,then

thetransfusionshouldbecontinued.Iftheyrecuragain,thetransfusionshouldbestopped

entirely.Ifsevere,orothersignsoccursuchascolic,pyrexia,cardiacarrhythmias,urticaria

andcollapse,thetransfusionshouldbestoppedandifnecessaryepinephrine(0.01mg/kg),

corticosteroidsandintravenoussalineadministered.Theseemergencydrugsshould

alwaysbeonhand.Flunixinmeglumineat0.25mg/kgmaybeusedprophylacticallyto

reducetheincidenceofsideeffects.

VolumeOverload.Volumeoverloadisapossiblehazardofplasmatransfusionespeciallyif

theadministrationiscarriedoutinfoalscompromisedinanywayortooquickly.Everyfoal

shouldbefullyclinicallyexaminedpriortotransfusionandinthecaseofcompromised

foalsthetransfusionshouldbemaintainedataslowrate,1litrefora50kgfoalorprorata

in1hour.Carefulmonitoringthroughoutthetransfusionisessential.Ifhyperventilating,

respiratorydistressortremblingoccurs,thetransfusionshouldbesloweddownorstopped

altogether.Diureticsmaybeusedinseverecases.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Administeronlyusingabloodgivingsettominimiseriskofself-injection.Incaseof

accidentalcontactwithskin,washaffectedareasthoroughlywithwarmsoapywater.

4.6Adversereactions(frequencyandseriousness)

ItshouldbenotedthatACD-Aisanexcipientandthatexcesscitratemaycauseareaction

intherecipientfoal.Thismaybeseenasmusclefasciculations,weaknessandcardiac

abnormalities.

RevisedMay2012

AN:01006/2011

Page3of6

TransfusionReactionsareveryrare;signsincludetachycardia,hyperventilatingand

trembling.

Anaphylaxisisveryrare,butcanoccurwithproductsofthisnature.Signsinclude

tachycardia,hyperventilatingandtrembling,orothersignssuchascolic,pyrexia,cardiac

arrhythmias,urticariaandcollapse.

VolumeOverloadisararehazardofplasmatransfusionespeciallyiftheadministrationis

carriedoutinfoalscompromisedinanywayortooquickly.Signsincluderespiratory

distress,hyperventilation,staggeringandcollapsewheninstandingrestraint.Additionally,

ifthefoalisinlateralrecumbencyfrothmaybeseenatthenostril.

Measurestoavoidtheseadversereactionsaredetailedinsection4.5

4.7Useduringpregnancy,lactationorlay

Donotuseinpregnantorlactatinghorses.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

SafetyandefficacydataareavailablewhichdemonstratethatHypermune-REcanbe

administeredonthesamedaybutnotmixedwithtetanusantitoxin.

NoinformationisavailableonthesafetyandefficacyofHypermune-REwhenusedwith

anyotherveterinarymedicinalproductexcepttheproductmentionedabove.Adecisionto

usethisproductbeforeorafteranyotherveterinarymedicinalproductthereforeneedsto

bemadeonacasebycasebasis.

Aswithcolostrumderivedpassiveimmunity,thepassiveimmunitytransferredby

Hypermune-REmayinterferewithresponsetovaccine.Itisrecommendedthatthisis

consideredwhenstartingavaccineprogrammewithdueadherencetothevaccine

manufacturer’sinstructions.

4.9 Amountstobeadministeredandadministrationroute

ForfoalswithFailureofPassiveTransfer

Hypermune-REmaybeadministeredtofoalsfrom24hoursto6daysofagewhereithas

beenshownaftertestingthattheyhavelowlevelsofserumIgG(lessthan4g/l).The

doserequiredisonelitrefora50kgfoal(andprorata,i.e.20mlperkg).

Abloodsampleshouldbecollectedfromthefoalapproximately24hourslaterandre-

testedforthelevelofserumIgG.Ifthisisstilllow,afurtherdosemaybeadministered.

Thisshouldbegivenwithin24 –48hoursofthefirstadministrationandbegiveninthe

samemannerasthefirst(intravenously,viaabloodgivingset,over15-20minutes).

ForfoalswithNormalPassiveTransfer

Thedoserequiredisonelitrefora50kgfoal(andprorata,i.e.20mlperkg).Tosustain

raisedlevelsofcirculatingRhodococcusequiantibodiesaseconddosemaybegivenat

approximately21dayslater.Thisshouldbegiveninthesamemannerasthefirst

(intravenously,viaabloodgivingset,over15-20minutes).

Methodofadministration

RevisedMay2012

AN:01006/2011

Page4of6

Therequireddoseisadministeredviaacatheterplacedinthejugularveinusingablood

givingsetequippedwithameshfilter.Theproductshouldbeadministeredslowly,

particularlyatthestart,andadministrationshouldtake15 –20minutes.Throughoutthe

administration,thefoalshouldbemonitoredforsignsofadversereactions.

Thawingshouldnottakeplaceinamicrowaveoven.Thelitrebagofplasmashouldbe

immersedonlyinwarmwateratnotmorethan40ºC.Awaterbathsuchasasinkfullof

domesticwarmwaterisideal.Astheplasmathawsandthewatercools,morewarmwater

maybeaddedasrequiredbuthotwater(notgreaterthanhandhot)mustbeavoidedasit

willdamagetheproteins.Theentirelitreofplasmashouldbebroughtslowlytobody

temperaturebeforeusetoensureallthecryoprecipitateisdissolved.Underoptimum

conditionsthiswholeprocessmaytake2-2½hours.Occasionallysmallamountsoffibrin

maystillbeseenfloatingintheplasma.Itisnotsignificantbutmustbefilteredoutbythe

filterinthebloodadministrationset.

Inspectforleakageandifapparentonthawingtheentirecontentsmustbediscarded.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noinformationisavailableontheeffectsofadministeringanoverdose

Volumeoverloadinfoals

Volumeoverloadisararehazardofplasmatransfusionespeciallyiftheadministrationis

carriedoutinfoalscompromisedinanywayortooquickly.

4.11Withdrawalperiod(s)

Zerodays.

5. IMMUNOLOGICALPROPERTIES

Tomodulatetheimmunesystembyprovidingequineimmunoglobulins,andspecific

antibodiestoRhodococcusequi.Fromlimitedfieldstudiesthereisatrendofreduced

severityofR.equidiseaseandareducedrequirementforintensiveantibiotictreatment

withtheuseofHypermuneREbytherecommendedschedule

ATCvetcode:QI05AM.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

AcidCitrateDextrose-A

6.2Incompatibilities

Donotmixwithanyotherveterinarymedicinalproduct.

RevisedMay2012

AN:01006/2011

Page5of6

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeoncethawed:24hours

6.4.Specialprecautionsforstorage

Storeinafreezer(-30°Cto-20°C)

HYPERMUNE-REshouldbehandledcarefullywhenbeingunpackedandstoredinthe

freezer.Thebubble-wrapshouldnotberemovedasitprotectsthebrittlefrozenplasticwhich

issusceptibletodamagefromcarelesshandlingsuchasbeingdroppedorknockedinthe

freezer.Whenthaweditshouldbestoredinarefrigerator.

6.5Natureandcompositionofimmediatepackaging

ThecontainerisaPVCwithDEHPone-litrehumanplasmasteriletransferbagwithtwo

protectivesterileports.Thewholebagisoverwrappedwithprotectivebubblewrapfor

storageandtransport.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

VeterinaryImmunogenicsLtd

CarletonHill

Penrith

Cumbria

CA118TZ

UnitedKingdom

8. MARKETINGAUTHORISATIONNUMBERS

Vm18513/4001 VPA10662/001/001

9. DATEOFFIRSTAUTHORISATION

03/04/2007(UK) 22/08/2008(IE)

10 DATEOFREVISIONOFTHETEXT

May2012

RevisedMay2012

AN:01006/2011

Page6of6

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable

18-12-2018

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Torrance, CA, Asclemed USA Inc is voluntarily recalling 20 lots of Dyural-40 and 61 lots of Dyural-80, to the user level. The products include recalled Sodium Chloride, USP, 0.9% manufactured by Fresenius Kabi, which has been recalled due to product labeling incorrectly stating stoppers do not contain latex.

FDA - U.S. Food and Drug Administration

17-12-2018


Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

28-11-2018

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

Health Canada

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

12-10-2018

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA - U.S. Food and Drug Administration

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

6-8-2018

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling 30 1-lb containers of Pat's Cat Turkey Cat Food and 40 2-lb containers of Ground Lamb Dog Food because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes can cause serious and sometimes fatal infections in animals eating the products.

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

12-6-2018

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

The lamp has incorrect lightbulb wattage information printed on a label on the sockets of the lamp. The incorrect labels indicate that each socket can support 40 W bulbs, however the product is only rated for each socket supporting a 25 W bulb. The use of lightbulbs with the incorrect wattage could potentially melt the power-switch, posing a burn hazard.

Health Canada

27-8-2018

Beromun (BELPHARMA s.a.)

Beromun (BELPHARMA s.a.)

Beromun (Active substance: Tasonermin (Tumor Necrosis Factor alfa-1a)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5699 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/206/T/40

Europe -DG Health and Food Safety

7-8-2018

ACMD meeting statement, Meeting 40, 12 April 2018

ACMD meeting statement, Meeting 40, 12 April 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

11-6-2018

Zydelig (Gilead Sciences Ireland UC)

Zydelig (Gilead Sciences Ireland UC)

Zydelig (Active substance: idelalisib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3765 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3843/T/40

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Active substance: Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin) - Orphan designation - Commission Decision (2018)3388 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/248/17

Europe -DG Health and Food Safety

16-5-2018

Elonva (Merck Sharp and Dohme B.V.)

Elonva (Merck Sharp and Dohme B.V.)

Elonva (Active substance: corifollitropin alfa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3049 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1106/T/40

Europe -DG Health and Food Safety